注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Elevation Oncology Inc是一家临床阶段的生物制药公司。该公司专注于在基因组定义的患者群体中开发针对癌症治疗的靶向疗法。它的重点是识别致癌驱动因素和其他驱动因素的改变,以及进行临床试验。其主要药物开发候选药物seribantumab是一种抗HER3单克隆抗体,是由神经调节蛋白1(NRG1)融合驱动的实体瘤的潜在靶向治疗,后者是被确定为致癌驱动因子改变的基因组改变。其NRG1是HER3的主要激活配体。该公司的临床试验CRESTONE是对患有任何来源的实体瘤的癌症患者进行的seribantumab II期研究,该实体瘤表达一种称为NRG1融合的基因组变化。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Steven Arnote Elms | 59 | 2019 | Independent Chairman of the Board |
R. Michael Carruthers | 66 | 2021 | Independent Director |
Joseph J. Ferra | 49 | 2021 | CEO, President & Director |
Timothy P. Clackson | 59 | 2020 | Independent Director |
Lori Anne Kunkel | 66 | - | Chairman of Scientific Advisory Board |
David Ross Camidge | - | - | Member of Scientific Advisory Board |
Darcy Mootz | - | 2024 | Independent Director |
Sai-Hong Ignatius Ou | - | - | Member of Scientific Advisory Board |
Dennis R. Benjamin | - | - | Member of Scientific Advisory Board |
Siraj M. Ali | - | - | Member of Scientific Advisory Board |
Alexander Drilon | - | - | Member of Scientific Advisory Board |
Alan Bart Sandler | 67 | 2024 | Director |
Julie Michele Cherrington | 66 | 2024 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核